Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity

Molecular Psychiatry

Volumn 7, Issue 1, 2002, Pages 32-43

  Farber, N B ^a   Kim, S H ^b   Dikranian, K ^a   Jiang, X P ^a   Heinkel, C ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b Korea University College of Medicine   (South Korea)

Author keywords

Alzheimer s disease; Dissociative anesthetics; Mk801; Neurodegeneration; Psychosis; Rats; Retrosplenial cortex; Rodents; Schizophrenia

Indexed keywords

6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMPA RECEPTOR; CLONIDINE; DIZOCILPINE; GLUTAMATE RECEPTOR ANTAGONIST; KAINIC ACID RECEPTOR; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SCOPOLAMINE;

ANIMAL MODEL; ARTICLE; BRAIN CORTEX; BRAIN INJURY; BRAIN REGION; CONTROLLED STUDY; DRUG MECHANISM; EPILEPSY; EXCITATION; FEMALE; HUMAN; INHIBITION KINETICS; NERVE CELL NETWORK; NERVE CONDUCTION; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PSYCHOMETRY; PSYCHOSIS; RAT; STROKE;

ADRENERGIC ALPHA-AGONISTS; ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANIMALS; CARBACHOL; CARBAZOLES; CEREBRAL CORTEX; CLONIDINE; DIZOCILPINE MALEATE; DRUG INTERACTIONS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; KAINIC ACID; MODELS, NEUROLOGICAL; MUSCARINIC ANTAGONISTS; NERVE TISSUE PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; PHENAZOCINE; PROSENCEPHALON; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUTAMATE; RECEPTORS, MUSCARINIC; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, SIGMA; SCOPOLAMINE;

EID: 85047700000     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000912     Document Type: Article

References (74)

1. Abnormal mental states induced by phencyclidine as a model of schizophrenia
2. Recent advances in the phenyclidine model of schizophrenia
3. The NMDA receptor-antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans
4. D-CPPene (SDZ EAA 494), a competitive NMDA antagonist. Results from animal models and first results in humans
5. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
6. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial
7. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia
8. NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers
9. Effects of prolonged infusion of the NMDA antagonist aptiganel hydrochloride (CNS 1102) in normal volunteers
10. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment in schizophrenia
11. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs
12. Phencyclidine, dizocilpine, and cerebrocortical neurons
13. NMDA antagonist neurotoxicity: Mechanism and prevention
14. Neuronal vacuolization and necrosis induced by the noncompetive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): A light and electron microscopic evaluation of the rat retrosplenial cortex
15. Quantitative analysis of factors influencing neuronal necrosis induced by MK-801 in the rat posterior cingulate/retrosplenial cortex
16. Dissimilar patterns of degeneration in brain following four different addictive stimulants
17. Competitive and non-competitive NMDA antagonists induce similar limbic degeneration
18. Multifocal brain damage induced by phencyclidine is augmented by pilocarpine
19. MK-801-induced neuronal damage in rats
20. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin
21. Disseminated corticolimbic neuronal degeneration induced in rat brain by MK-801: Potential relevance to Alzheimer's disease
22. Glutamate receptor dysfunction and schizophrenia
23. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine
24. N-methyl-D-aspartate mediated responses decrease with age in Fischer 344 rat brain
25. Loss of NMDA, but not GABA-A, binding in the brais of aged rats and monkeys
26. Age-related changes in excitatory amino acid receptors in two mouse strains
27. Dizocilpine binding to cerebral cortical membranes from developing and ageing mice
28. Decreased expression of N-methyl-D-aspartate receptor 1 messenger RNA in select regions of Alzheimer brain
29. Excitatory transmitter neurotoxicity and Alzheimer's disease
30. Excitotoxic neurodegeneration in Alzheimer disease; new hypothesis and new therapeutic strategies
31. Glutamatergic transmission: Therapeutic prospects for schizophrenia and Alzheimer's disease
32. Structural organization of cingulate cortex: Areas, neurons, and somatodendritic transmiter receptors
33. Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity
34. 2 adrenergic agonists prevent MK-801 neurotoxicity
35. 2A receptors prevent NMDA antagonist neurotoxicity
36. Isoflurane and propofol block neurotoxicity caused by MK-801 in the rat posterior cingulate/retrosplenial cortex
37. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells
38. 2-adrenergic agonists
39. MK-801 and ketamine induce heat shock protein HSP72 in injured neurons in posterior cingulate and retrosplenial cortex
40. DNQX inhibits phencyclidine (PCP) and ketamine induction of the hsp70 heat shock gene in the rat cingulate and retrosplenial cortex
41. The effects of MK-801 on aspartate and glutamate levels in the anterior cingulate and retrosplenial cortices: An in vivo microdialysis study
42. Cholinergic innervation of cortex by the basal forebrain: Cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey
43. Cholinergic systems in mammalian brain and spinal cord
44. Glutamatergic regulation of acetylcholine output in different brain regions: A microdialysis study in the rat
45. MK-801 increases endogenous acetylcholine release in the rat parietal cortex: A study using brain microdialysis
46. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex
47. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine
48. Flip and flop: A cell-specific functional switch in glutamate-operated channels of the CNS
49. Hippocampal neurons exhibit cyclothiazide-sensitive rapidly desensitizing responses to kainate
50. Halothane prevents MK-801 neurotoxicity in the rat cingulate cortex
51. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats
52. NMDA receptor antagonists decrease GABA outflow from the septum and increase acetylcholine outflow from the hippocampus: A microdialysis study
53. Glutamatergic modulation of cortical acetylcholine release in the rat: A combined in vivo microdialysis, retrograde tracing and immunohistochemical study
54. 14C] glucose
55. Localisation of phencyclidine-induced changes in brain energy metabolism
56. Ketamine-induced changes in regional glucose utilization in the rat brain
57. 3H]2-deoxyglucose capture in the hippocampus and dentate gyrus of ketamine-anesthetized rat
58. Local changes in cerebral glucose utilization during ketamine anesthesia
59. The influence of droperidol, diazepam and physostigmine on ketamine-induced behavior and brain regional glucose utilization in rat
60. Altered metabolic activity in the cerebral cortex of rats exposed to ketamine
61. The influence of ketamine on regional brain glucose use
62. Effects of MK-801 upon local cerebral glucose utilisation in conscious rats and in rats anaesthetised with halothane
63. Competitive (AP7) and non-competitive (MK-801) NMDA receptor antagonists differentially alter glucose utilization in rat cortex
64. Intracerebroventricular application of competitive and non-competitive NMDA antagonists induce similar effects upon rat hippocampal electroencephalogram and local cerebral glucose utilization
65. Delayed regional metabolic actions of phencyclidine
66. Comparison of the patterns of altered cerebral glucose utilisation produced by competitive and non-competitive NMDA receptor antagonists
67. Metabolic mapping of the rat brain after subanesthetic doses of ketamine: Potential relevance to schizophrenia
68. Sigma receptors: Biology and function
69. The glutamate synapse in neuropsychiatric disorders: Focus on schizophrenia and Alzheimer's disease
70. Glycine agonists: What can they teach us about schizophrenia?
71. The role of NMDA receptor hypofunction in idiopathic psychotic disorders
72. Interconnections between the thalamus and retrosplenial cortex in the rodent brain
73. Heat shock protein HSP72 induced in rat retrosplenial cortex by dizocilpine is caused by the thalamo-cortical neurons in anterior thalamus